Abstract
Despite advances in the treatment of glioblastoma (GBM), median survival is 12–15 months. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is acknowledged as a predictive marker for temozolomide (TMZ) treatment. When MGMT promoter values fall into a “methylated” range, a better response to chemotherapy is expected. However, a cutoff that discriminates between “methylated” and “unmethylated” status has yet to be defined. We aimed to identify the best cutoff value and to find out whether variability in methylation profiles influences the predictive capacity of MGMT promoter methylation. Data from 105 GBM patients treated between 2008 and 2013 were analyzed. MGMT promoter methylation status was determined by analyzing 10 CpG islands by pyrosequencing. Patients were treated with radiotherapy followed by TMZ. MGMT promoter methylation status was classified into unmethylated 0–9 %, methylated 10–29 % and methylated 30–100 %. Statistical analysis showed that an assumed methylation cutoff of 9 % led to an overestimation of responders. All patients in the 10–29 % methylation group relapsed before the 18-month evaluation. Patients with a methylation status ≥30 % showed a median overall survival of 25.2 months compared to 15.2 months in all other patients, confirming this value as the best methylation cutoff. Despite wide variability among individual profiles, single CpG island analysis did not reveal any correlation between single CpG island methylation values and relapse or death. Specific CpG island methylation status did not influence the predictive value of MGMT. The predictive role of MGMT promoter methylation was maintained only with a cutoff value ≥30 %.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McGirt MJ, Than KD, Weingart JD et al (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583–588. doi:10.3171/2008.5.17557
Brennan CW, Verhaak RGW, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. doi:10.1016/j.cell.2013.09.034
Moskowitz SI, Jin T, Prayson RA (2006) Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 76:193–200
Shinojima N, Kochi M, Hamada J et al (2004) The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101:219–226
Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery. 62:753–766. doi:10.1227/01.neu.0000318159.21731.cf
Sanai N, Polley MY, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg 115:3–8. doi:10.3171/2011.2.JNS10998
Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol 7:392–401
Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
Shah N, Lin B, Sibenaller Z et al (2011) Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6:e16146. doi:10.1371/journal.pone.0016146
Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350. doi:10.1002/ijc.27385
Lattanzio L, Borgognone M, Mocellini C et al (2014) MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. Int J Biol Markers 30(2):e208–e216
Håvik AB, Brandal P, Honne H et al (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med 10:36
Preusser M, Berghoff AS, Manzl C et al (2014) Clinical neuropathology practice news 1–2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol 33:6–14
Quillien V, Lavenu A, Sanson M et al (2014) Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol 116:487–496. doi:10.1007/s11060-013-1332-y
Wick W, Weller M, Van den Bent M et al (2014) MGMT testing—the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10:372–385. doi:10.1038/nrneurol.2014.100
Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124–131. doi:10.1038/sj.bjc.6605127
Malley DS, Hamoudi RA, Kocialkowski S et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651–661. doi:10.1007/s00401-011-0803-5
Wen YP, Macdonald RD, Reardon AD et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro oncology working group. J Clin Oncol 28:1963–1972
Xie H, Tubbs R, Yang B (2015) Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Int J Clin Exp Pathol 8:636–642
Quillien V, Lavenu A, Karayan-Tapon L et al (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201–4211. doi:10.1002/cncr.27392
Lai K, Chen Y, Guan X et al (2014) Genome-wide methylation analyses in glioblastoma multiforme. PLoS One 9:e89376. doi:10.1371/journal.pone.0089376
van Vlodrop IJ, Niessen HEC, Derks S et al (2011) Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 17:4225–4231. doi:10.1158/1078-0432.CCR-10-3394
Bady P, Sciuscio D, Diserens AC et al (2012) MGMT methylation analysis of glioblastoma on the infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560. doi:10.1007/s00401-012-1016-2
Acknowledgments
Collaborating authors: Salvatore Roberto Bellia (Radiotherapy Unit) and Nada Riva (Department of Medical Oncology), IRCCS IRST, Meldola; Patrizia Cenni (Neuroradiology Unit) and Claudio Dazzi (Medical Oncology Unit), S. Maria delle Croci Hospital, Ravenna; Alessandro Gamboni (Medical Oncology Unit), Degli Infermi Hospital, Faenza; Roberto Montanari (Neuroradiology Unit), Umberto I Hospital, Lugo; Anna Maria Cremonini and Luigino Tosatto (Neurosurgery Unit), Franceschi Giancarlo (Neuroradiology Unit), Evandro Nigrisoli (Pathology Unit), and Maria Grazia Passarin (Neurology Unit), Bufalini Hospital, Cesena; Giuseppe Pasini (Department of Oncology) and Michele Sintini (Neuroradiology Unit), Infermi Hospital, Rimini; Antonio Polselli (Medical Oncology Unit) Cervesi Hospital, Cattolica; Italy. The authors thank Gráinne Tierney for editorial assistance.
Author contributions
Conception and design: Giovanni Brigliadori, Daniele Calistri, Marina Faedi and Dino Amadori. Provision of study materials or patients: Marina Faedi, Serenella Cerasoli, Elisabetta Melegari and Dino Amadori. Collection and assembly of data: Giovanni Brigliadori, Claudia Rengucci, Elisabetta Melegari and Serenella Cerasoli. Data analysis and interpretation: Giovanni Brigliadori, Flavia Foca, Monia Dall’Agata, Daniele Calistri. Manuscript writing: all authors. Final approval of manuscript: all authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
There are no conflicts of interest to declare.
Additional information
Daniele Calistri and Marina Faedi equally contributed to the work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Brigliadori, G., Foca, F., Dall’Agata, M. et al. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. J Neurooncol 128, 333–339 (2016). https://doi.org/10.1007/s11060-016-2116-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-016-2116-y